AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2018
Jan 24, 2018
31523_dirs_2018-01-24_bd3112e3-336e-4db0-81f8-8317b6cf543b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2018-01-22
Reporting Person: Campbell Bradley L (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-01-22 | Common Stock | M | 32500 | $10.21 | Acquired | 186600 | Direct |
| 2018-01-22 | Common Stock | S | 32500 | $15.9191 | Disposed | 154100 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-01-22 | Stock Options (right to buy) | $10.21 | M | 32500 | Disposed | 2018-02-05 | Common Stock (32500) | Direct |
Footnotes
F1: The sales of shares of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017.
F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.73 to $16.24. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: All of the options were fully vested and exercisable as of January 22, 2018.